IP Library › Granted Patent US 10,273,284
Granted Patent B2
US 10,273,284 · App. 15/658,475 · Granted Apr 30, 2019

Cytokine-based fusion proteins for treatment of immune disorders

Inventor: Mark D. Mannie (Greenville, NC)
Assignee: East Carolina University
C07K14/7155A61K38/17A61K38/1793A61K38/2013A61K38/2026A61K38/2066A61K38/2086A61K38/215A61K39/0008A61K39/35A61K47/642A61K47/646C07K14/47C07K14/4713C07K14/52C07K14/5406C07K14/5428C07K14/5437C07K14/5446C07K14/55C07K14/565C07K19/00A61K9/0019C07K2319/33C07K2319/40C07K2319/74C07K2319/75C12N15/09C12N15/62C12N15/63
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,273,284
App. No.
15/658,475
Granted
Apr 30, 2019
Kind
B2
Abstract

The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.

Claims (3)

1. A method of eliciting a tolerogenic response in a subject in need thereof, comprising administering to the subject at least one fusion protein, wherein said fusion protein comprises (i) a myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocytic basic protein (MOBP), and any combination thereof, and (ii) an anti-inflammatory cytokine selected from the group consisting of interleukin (IL) 1 receptor alpha (IL-1RA) IL-2, IL-4, IL-10, IL-13, IL-16, interferon-beta (IFN-β), and any combination thereof.

2. The method of claim 1 , wherein the tolerogenic response modulates an antigen-specific immune response.

3. The method of claim 1 , wherein the tolerogenic response is an active tolerance mechanism or a sustained tolerogenic response.

Continuity (4)
Division 14530270 · Oct 31, 2014
Continuation 12447389
Provisional Application 60863692 · Oct 31, 2006
Related Publication 20170320933A1 · Nov 9, 2017
Cited By (1)
US 12,569,556